| Stephanie Jo Anderson, PHARMD | |
|
221 W 4th St, Duluth, MN 55806-2719 | |
| (218) 249-4150 | |
| (218) 279-4007 |
| Full Name | Stephanie Jo Anderson |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 221 W 4th St, Duluth, Minnesota |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023328853 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 118822 (Minnesota) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Stephanie Jo Anderson, PHARMD 221 W 4th St, Duluth, MN 55806-2719 Ph: (218) 879-1227 | Stephanie Jo Anderson, PHARMD 221 W 4th St, Duluth, MN 55806-2719 Ph: (218) 249-4150 |
News Archive
Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc. announced today that lubiprostone met the primary endpoint in a phase 3 clinical trial for the treatment of opioid-induced bowel dysfunction (OBD) in patients with chronic, non-cancer pain, excluding those taking methadone.
Regeneron Pharmaceuticals, Inc. announced that the company submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration (wet AMD). Under the Prescription Drug User Fee Act (PDUFA), the goal for a standard review time from submission to FDA action is ten months.
The occupational health and safety regulation regarding the coronavirus has been in effect throughout Germany since the end of January. It requires companies to offer their employees the opportunity to work from home, as far as their work permits.
Significantly decreased blood sugar levels over time - and increased well-being. These are just some of the results of a long-term study at Sahlgrenska Academy of continuous glucose monitoring in persons with type 1 diabetes.
Patients whose acute myelogenous leukemia (AML) had relapsed or was resistant to chemotherapy and those who were deemed unable to tolerate chemotherapy experienced responses to the selective BCL-2 inhibitor venetoclax (Venclexta), with complete remissions in some, according to phase II clinical trial data.
› Verified 9 days ago
Jordan Tichenor, Pharmacist Medicare: Accepting Medicare Assignments Practice Location: 400 E 3rd St, Duluth, MN 55805 Phone: 218-786-3737 Fax: 187-278-3282 | |
Donald P Gibson, PHARMACIST Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1502 London Road, Suite 101, Duluth, MN 55812 Phone: 218-733-1110 Fax: 218-733-1112 | |
Dr. David Michael Malenowski I, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1201 Miller Trunk Hwy, Duluth, MN 55811 Phone: 218-727-8157 Fax: 218-727-4261 | |
Anthony Richard Grand, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 915 E 1st St, Duluth, MN 55805 Phone: 218-249-5555 | |
Dr. Karen Ms Bastianelli, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1208 Kirby Dr, 380 Kirby Plaza, Duluth, MN 55812 Phone: 218-726-6026 Fax: 218-726-6500 | |
Michael Kozlovski, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1201 Miller Trunk Hwy, Duluth, MN 55811 Phone: 218-727-8157 Fax: 218-727-4261 |